Last reviewed · How we verify
ExPEC9V
ExPEC9V is a vaccine designed to stimulate immune responses against extraintestinal pathogenic E. coli (ExPEC) strains.
ExPEC9V is a vaccine designed to stimulate immune responses against extraintestinal pathogenic E. coli (ExPEC) strains. Used for Prevention of urinary tract infections caused by ExPEC, Prevention of bacteremia and invasive infections caused by ExPEC.
At a glance
| Generic name | ExPEC9V |
|---|---|
| Also known as | VAC52416,, JNJ-78901563, VAC52416; JNJ-78901563 |
| Sponsor | Janssen Research & Development, LLC |
| Drug class | Bacterial vaccine |
| Target | Extraintestinal pathogenic E. coli (ExPEC) antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
ExPEC9V targets nine serotypes of extraintestinal pathogenic E. coli, which are responsible for urinary tract infections, bacteremia, and other invasive infections. The vaccine works by inducing both humoral and cellular immune responses to prevent infection and reduce disease severity caused by these pathogenic strains.
Approved indications
- Prevention of urinary tract infections caused by ExPEC
- Prevention of bacteremia and invasive infections caused by ExPEC
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Fatigue
Key clinical trials
- A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years (PHASE3)
- A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ExPEC9V CI brief — competitive landscape report
- ExPEC9V updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI